Veru Inc. sells Entadfi to Blue Water Vaccines
Veru Inc., a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, announced the sale of its Entadfi (finasteride and tadalafil) capsules business for benign prostatic hyperplasia (BPH) to Blue Water Vaccines, Inc. for $20 million and up to an additional $80 million from sales milestones
“The sale of Entadfi and revenues from our FC2 business provide Veru with financial flexibility and resources to advance our important drug candidates, enobosarm for 2nd line AR+ ER+ HER2- metastatic breast cancer and sabizabulin for SARS-CoV-2 viral ARDS, that could yield Phase III clinical trial data in 2024,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
